Moonlake Immunotherapeutics Has Completed Randomization Of The Target 200 Patients, Several Weeks Ahead Of Schedule, In Its Global Phase 2 ARGO Trial Evaluating Nanobody Sonelokimab In Active Psoriatic Arthritis
Portfolio Pulse from Benzinga Newsdesk
Moonlake Immunotherapeutics has completed the randomization of the target 200 patients in its global Phase 2 ARGO trial evaluating Nanobody Sonelokimab in active psoriatic arthritis, several weeks ahead of schedule.
July 25, 2023 | 12:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moonlake Immunotherapeutics' early completion of patient randomization for its Phase 2 ARGO trial could potentially accelerate the development timeline of Sonelokimab.
The early completion of patient randomization for the Phase 2 ARGO trial indicates efficient trial management and could potentially accelerate the development timeline of Sonelokimab. This could be seen as a positive development by investors, potentially leading to a short-term increase in the stock price of Moonlake Immunotherapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100